Scholar Rock (NASDAQ:SRRK) Director Sells $164,068.22 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) Director Kristina Burow sold 3,053 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total transaction of $164,068.22. Following the completion of the sale, the director directly owned 114,657 shares in the company, valued at $6,161,667.18. This trade represents a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $56.03 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. The firm has a market cap of $6.71 billion, a P/E ratio of -15.61 and a beta of 0.67. The firm’s 50 day moving average price is $48.99 and its 200-day moving average price is $46.85. Scholar Rock Holding Corporation has a one year low of $27.07 and a one year high of $57.80.

Get Scholar Rock alerts:

Scholar Rock (NASDAQ:SRRK – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the business posted ($0.67) EPS. As a group, equities research analysts predict that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Siren L.L.C. increased its holdings in Scholar Rock by 17.0% during the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after purchasing an additional 1,575,008 shares during the period. Redmile Group LLC boosted its stake in shares of Scholar Rock by 73.7% in the 1st quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock valued at $445,715,000 after buying an additional 3,845,775 shares during the period. Wellington Management Group LLP boosted its stake in shares of Scholar Rock by 26.7% in the 4th quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock valued at $253,703,000 after buying an additional 1,213,541 shares during the period. Vanguard Group Inc. grew its position in shares of Scholar Rock by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock worth $228,860,000 after buying an additional 280,538 shares in the last quarter. Finally, State Street Corp grew its position in shares of Scholar Rock by 7.2% during the fourth quarter. State Street Corp now owns 4,034,434 shares of the company’s stock worth $177,717,000 after buying an additional 271,331 shares in the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wedbush boosted their price objective on Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a report on Wednesday, April 1st. HC Wainwright lifted their target price on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Canaccord Genuity Group began coverage on shares of Scholar Rock in a research note on Monday, April 20th. They set a “buy” rating and a $62.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research report on Thursday, June 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $56.00.

Get Our Latest Research Report on Scholar Rock

About Scholar Rock

(Get Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

Read More

• Five stocks we like better than Scholar Rock
• A Market Panic Just Discounted the AI Highway’s Tollbooth
• Why Exxon Could Be the Market’s Next Big Comeback Stock
• The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
• Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.